Coronary heart disease (CHD) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO) reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%. In practical terms, that means that many who “look healthy” go on to have CHD and preventable cardiac events such as a heart attack.
For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops. Healthcare providers ask about cholesterol levels, blood pressure, smoking history, diabetes status, family history and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full biological picture of how heart disease develops. This gap leaves a significant blind spot in preventive medicine.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level. By focusing on the molecular underpinnings of CHD, the company aims to identify individuals at risk who would otherwise be missed by traditional screening. The implications for patients are substantial: earlier detection could lead to earlier interventions, potentially reducing the number of preventable cardiac events.
What makes CHD numbers particularly troubling is that so much of this is preventable. With improved diagnostic tools, healthcare providers could better target preventive measures such as lifestyle modifications, statin therapy, or other interventions to those who truly need them. The current standard of care leaves a large portion of the at-risk population undiagnosed until a major event occurs.
The news from Cardio Diagnostics arrives at a time when the limitations of conventional risk assessment are becoming increasingly recognized in the medical community. The company’s epigenetic and genetic approach represents a shift toward more personalized medicine, where risk is assessed based on an individual's unique biological profile rather than population-level averages.
For the broader healthcare industry, the adoption of molecular precision tools could reshape how cardiovascular risk is evaluated, potentially leading to updated clinical guidelines and reimbursement models. If widely implemented, such tests could reduce the burden of CHD on the healthcare system by preventing costly hospitalizations and procedures.
Investors and stakeholders can find the latest news and updates relating to CDIO in the company’s newsroom at https://ibn.fm/CDIO. For full terms of use and disclaimers, refer to the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
Forward-looking statements in this article involve risks and uncertainties, including those detailed in the company's SEC filings. Undue reliance should not be placed on these forward-looking statements.
